Literature DB >> 32759257

Response to: 'Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis' by Singer et al.

Alfred Hyoungju Kim1, Jeffrey A Sparks2, Manuel Francisco Ugarte-Gil3, Maximilian F Konig4, Peter Korsten5, Francis Berenbaum6.   

Abstract

Entities:  

Keywords:  arthritis; hydroxychloroquine; lupus erythematosus; rheumatoid; systemic

Year:  2020        PMID： 32759257      PMCID： PMC8075121          DOI： 10.1136/annrheumdis-2020-218683

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  11 in total

1.  Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2.

Authors:  Markus Hoffmann; Kirstin Mösbauer; Heike Hofmann-Winkler; Artur Kaul; Hannah Kleine-Weber; Nadine Krüger; Nils C Gassen; Marcel A Müller; Christian Drosten; Stefan Pöhlmann
Journal:  Nature       Date:  2020-07-22       Impact factor: 49.962

2.  Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19.

Authors:  Maximilian F Konig; Alfred Hj Kim; Marc H Scheetz; Elizabeth R Graef; Jean W Liew; Julia Simard; Pedro M Machado; Milena Gianfrancesco; Jinoos Yazdany; Daman Langguth; Philip C Robinson
Journal:  Ann Rheum Dis       Date:  2020-05-07       Impact factor: 19.103

3.  Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs.

Authors:  Xabier Michelena; Helena Borrell; Mireia López-Corbeto; María López-Lasanta; Estefanía Moreno; María Pascual-Pastor; Alba Erra; Mayte Serrat; Esther Espartal; Susana Antón; Gustavo Adolfo Añez; Raquel Caparrós-Ruiz; Andrea Pluma; Ernesto Trallero-Araguás; Mireia Barceló-Bru; Miriam Almirall; Juan José De Agustín; Jordi Lladós; Antonio Julià; Sara Marsal
Journal:  Semin Arthritis Rheum       Date:  2020-05-16       Impact factor: 5.532

4.  Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry.

Authors:  Milena Gianfrancesco; Kimme L Hyrich; Jinoos Yazdany; Pedro M Machado; Philip C Robinson; Sarah Al-Adely; Loreto Carmona; Maria I Danila; Laure Gossec; Zara Izadi; Lindsay Jacobsohn; Patricia Katz; Saskia Lawson-Tovey; Elsa F Mateus; Stephanie Rush; Gabriela Schmajuk; Julia Simard; Anja Strangfeld; Laura Trupin; Katherine D Wysham; Suleman Bhana; Wendy Costello; Rebecca Grainger; Jonathan S Hausmann; Jean W Liew; Emily Sirotich; Paul Sufka; Zachary S Wallace
Journal:  Ann Rheum Dis       Date:  2020-05-29       Impact factor: 19.103

Review 5.  Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist.

Authors:  Elizabeth R Graef; Jean W Liew; Alfred Hj Kim; Jeffrey A Sparks; Michael S Putman; Julia F Simard; Emily Sirotich; Francis Berenbaum; Alí Duarte-García; Rebecca Grainger; Carly Harrison; Maximilian F Konig; Peter Korsten; Laurie Proulx; Dawn P Richards; Philip C Robinson; Sebastian E Sattui; Manuel Francisco Ugarte-Gil; Kristen J Young
Journal:  Ann Rheum Dis       Date:  2020-04-15       Impact factor: 27.973

6.  Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases.

Authors:  Jose L Pablos; Lydia Abasolo; Jose M Alvaro-Gracia; Francisco J Blanco; Ricardo Blanco; Isabel Castrejón; David Fernandez-Fernandez; Benjamín Fernandez-Gutierrez; María Galindo-Izquierdo; Miguel A Gonzalez-Gay; Sara Manrique-Arija; Natalia Mena Vázquez; Antonio Mera Varela; Miriam Retuerto; Alvaro Seijas-Lopez
Journal:  Ann Rheum Dis       Date:  2020-06-12       Impact factor: 19.103

7.  Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?

Authors:  Ennio Giulio Favalli; Sara Monti; Francesca Ingegnoli; Silvia Balduzzi; Roberto Caporali; Carlomaurizio Montecucco
Journal:  Arthritis Rheumatol       Date:  2020-09-06       Impact factor: 15.483

8.  Prevalence of COVID-19 among patients with chronic inflammatory rheumatic diseases treated with biologic agents or small molecules: A population-based study in the first two months of COVID-19 outbreak in Italy.

Authors:  Luca Quartuccio; Francesca Valent; Enrico Pasut; Carlo Tascini; Salvatore De Vita
Journal:  Joint Bone Spine       Date:  2020-05-20       Impact factor: 5.263

9.  Factors associated with COVID-19-related death using OpenSAFELY.

Authors:  Elizabeth J Williamson; Alex J Walker; Krishnan Bhaskaran; Seb Bacon; Chris Bates; Caroline E Morton; Helen J Curtis; Amir Mehrkar; David Evans; Peter Inglesby; Jonathan Cockburn; Helen I McDonald; Brian MacKenna; Laurie Tomlinson; Ian J Douglas; Christopher T Rentsch; Rohini Mathur; Angel Y S Wong; Richard Grieve; David Harrison; Harriet Forbes; Anna Schultze; Richard Croker; John Parry; Frank Hester; Sam Harper; Rafael Perera; Stephen J W Evans; Liam Smeeth; Ben Goldacre
Journal:  Nature       Date:  2020-07-08       Impact factor: 49.962
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.